Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
For people with type 2 diabetes (T2D) and chronic kidney disease (CKD), both finerenone and sodium-glucose cotransporter 2 inhibitors (SGLT-2Is) improve the kidney outcome, but their combination therapy remains unclear in real-world practice.
This retrospective study recruited people with T2D and CKD receiving finerenone on SGLT-2Is or SGLT-2Is alone from May 2019 to March 2025. Propensity scores for initiators of finerenone on SGLT-2Is were 1:4 matching with initiators of SGLT-2Is. Propensity score included baseline covariates defined by directed acyclic graphs, including sociodemographic and metabolic factors, drugs, and eGFR slope before treatment. The primary outcome was the time from drug initiation to ≥30% decline in eGFR by Cox models. The secondary outcome was the change in chronic eGFR slope by a piecewise linear mixed-effects model.
Of 652 eligible patients, 581 initiated SGLT-2Is and 71 initiated finerenone on basis of SGLT-2Is. After matching, the analytic cohort included 228 SGLT-2Is initiators and 69 finerenone initiators on SGLT-2Is. The mean age was 54.5 years, with a mean eGFR of 68.8 mL/min/1.73 m² and baseline eGFR slope of -2.1 mL/min/1.73 m²/year. Over a median follow-up of 18.1 months, people receiving finerenone and SGLT-2Is are associated with a reduced risk of ≥30% eGFR decline (hazard ratio: 0.26; 95% CI: 0.11 to 0.57; p < 0.001) compared to those received SGLT-2Is only. Subgroup analyses revealed consistent benefits of adding finerenone on SGLT-2Is across categories of age, baseline eGFR, urinary albumin-to-creatinine ratio (UACR), pre-treatment eGFR slope, and RASIs. The between-group difference in post-treatment chronic eGFR slope was -0.74 mL/min/1.73 m²/year (95% CI: -2.95 to 1.45; p = 0.506). Of those patients with a rapid pre-treatment eGFR decline, the finerenone on SGLT-2Is group experienced significantly greater decline compared to the SGLT-2Is group (mean difference: -6.28 mL/min/1.73 m²/year; 95% CI: -11.81 to -0.75; p = 0.026).
For most people with T2D-CKD receiving SGLT-2Is, adding finerenone is associated with slowed kidney deterioration compared to those receiving SGLT-2Is alone. However, for those with rapid eGFR decline, adding finerenone to SGLT-2Is is associated with accelerated eGFR decline compared to SGLT-2Is alone.
